Does Selank act on opioid receptors?

Reported work describes inhibition of enkephalin-degrading enzymes rather than direct receptor binding. It preserves the body's own enkephalins instead of supplying an agonist.

What is an enkephalinase?

A collective term for peptidases that break down enkephalins, clearing them from circulation and from synaptic space.

Is this the same as how DPP-4 inhibitors work?

The logic is analogous — prolong an endogenous peptide rather than supply an analogue — though the peptides and enzymes involved are entirely different.

Selank (Tuftsin Analogue)

Selank's Enkephalinase Mechanism

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Selank's most specifically characterised activity is inhibition of enkephalin-degrading enzymes. Rather than acting at opioid receptors itself, it slows the breakdown of endogenous enkephalins — particularly leu-enkephalin — so the body's own signalling persists longer. This was measured directly on plasma enkephalinase activity.

Key facts

Target: Enkephalin-degrading enzymes
Effect: Extended endogenous enkephalin half-life
Enkephalin most cited: Leu-enkephalin
Not: An opioid receptor ligand
Measured in: Plasma enkephalinase activity
Key references: PMID 11550013, PMID 12432865

What enkephalins are

Enkephalins are short endogenous opioid peptides — met-enkephalin and leu-enkephalin, each five residues — produced from proenkephalin and acting at delta and mu opioid receptors. They are part of the body's own opioid signalling system, and like most signalling peptides they are cleared rapidly by specific peptidases collectively referred to as enkephalinases.

The difference between agonism and degradation inhibition

This distinction is the whole point and it is routinely muddled. An opioid agonist binds the receptor and activates it directly, at whatever concentration is administered, wherever the drug reaches. A degradation inhibitor does not touch the receptor. It allows the endogenous ligand already being released to persist longer, which means the effect is bounded by the body's own release patterns and occurs only where enkephalins are actually being produced.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

What was measured

Work published in the Bulletin of Experimental Biology and Medicine in 2001 reported an inhibitory effect of Selank on enkephalin-degrading enzymes, proposed as a mechanism for its observed activity. A 2002 study in the same journal examined effects on behavioural measures alongside plasma enkephalin-degrading enzyme activity, linking the biochemical observation to a behavioural one.

Why this mechanism is interesting pharmacologically

Modulating a system by slowing clearance of its endogenous ligand is a fundamentally different intervention from supplying an exogenous agonist. The effect is self-limiting in a way direct agonism is not, because it depends on there being endogenous ligand to preserve. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue — and the comparison is instructive, because that class produces notably smaller effects than the receptor agonists.

What this does not establish

Enzyme inhibition measured in plasma is a biochemical observation. It does not by itself establish a functional consequence in an organism, and the interventional work here is preclinical. The mechanism is well described; what it produces in humans rests on a clinical literature that is largely Russian-language and difficult to assess independently.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does Selank act on opioid receptors?: Reported work describes inhibition of enkephalin-degrading enzymes rather than direct receptor binding. It preserves the body's own enkephalins instead of supplying an agonist.
What is an enkephalinase?: A collective term for peptidases that break down enkephalins, clearing them from circulation and from synaptic space.
Is this the same as how DPP-4 inhibitors work?: The logic is analogous — prolong an endogenous peptide rather than supply an analogue — though the peptides and enzymes involved are entirely different.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum